Goldman Sachs’s Phathom Pharmaceuticals PHAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.96M Buy
626,196
+234,151
+60% +$2.96M ﹤0.01% 3373
2025
Q4
$6.5M Buy
392,045
+240,013
+158% +$3.43M ﹤0.01% 3508
2025
Q3
$1.79M Sell
152,032
-40,494
-21% -$418K ﹤0.01% 4581
2025
Q2
$1.85M Buy
192,526
+4,652
+2% +$25.7K ﹤0.01% 4245
2025
Q1
$1.18M Sell
187,874
-224,388
-54% -$1.36M ﹤0.01% 4552
2024
Q4
$3.35M Sell
412,262
-21,959
-5% -$272K ﹤0.01% 3836
2024
Q3
$7.85M Buy
434,221
+16,937
+4% +$237K ﹤0.01% 2940
2024
Q2
$4.3M Buy
417,284
+209,912
+101% +$2.16M ﹤0.01% 3296
2024
Q1
$2.2M Sell
207,372
-2,839
-1% -$24.1K ﹤0.01% 3800
2023
Q4
$1.92M Buy
210,211
+71,711
+52% +$618K ﹤0.01% 3955
2023
Q3
$1.44M Sell
138,500
-16,168
-10% -$222K ﹤0.01% 4012
2023
Q2
$2.21M Buy
154,668
+105,987
+218% +$1.22M ﹤0.01% 3801
2023
Q1
$348K Sell
48,681
-25,331
-34% -$223K ﹤0.01% 5033
2022
Q4
$830K Buy
74,012
+16,670
+29% +$172K ﹤0.01% 4546
2022
Q3
$635K Buy
57,342
+4,970
+9% +$47.4K ﹤0.01% 4813
2022
Q2
$442K Buy
52,372
+24,035
+85% +$247K ﹤0.01% 5170
2022
Q1
$386K Sell
28,337
-5,780
-17% -$93.4K ﹤0.01% 5504
2021
Q4
$671K Buy
34,117
+26,954
+376% +$634K ﹤0.01% 5160
2021
Q3
$230K Buy
+7,163
New +$238K ﹤0.01% 5656
2021
Q1
Sell
-44,078
Closed -$1.46M 6281
2020
Q4
$1.46M Buy
+44,078
New +$1.79M ﹤0.01% 3946
2020
Q1
Sell
-6,492
Closed -$202K 5478
2019
Q4
$202K Buy
+6,492
New +$163K ﹤0.01% 4892

Other funds holding PHAT